After two months of treatment, the intestinal microbial diversity of ACS patients taking rosuvastatin showed an increasing trend, while the intestinal microbial diversity of ACS patients taking atorvastatin showed the opposite decreasing trend.
← all excerpts
Insights from metagenomics into gut microbiome associated with acute coronary syndrome therapy.
1
—
—